Does Intuitive Surgical, Inc. (ISRG) have an economic moat?

MoatScan AI rates Intuitive Surgical, Inc. (ISRG) 65/100 for moat strength, assessed across five sources of competitive advantage: network effects, switching costs, intangible assets, cost advantages and efficient scale. Intuitive Surgical’s moat is anchored by the da Vinci ecosystem: a massive installed base, surgeon training advantages, recurring instruments and service revenue, and a long record of regulatory clearances and clinical…

What is Intuitive Surgical, Inc.'s moat score?

Intuitive Surgical, Inc. (ISRG) has a moat score of 65/100. The score is a weighted average of five pillar ratings: network effects, switching costs, intangible assets, cost advantages, and efficient scale. A higher score means the competitive advantages MoatScan AI identifies are wider and more durable.

Is ISRG stock overvalued or undervalued?

MoatScan AI answers this by estimating ISRG's intrinsic value with a discounted cash flow (DCF) model, then comparing that estimate to the current market price. A share price meaningfully below the estimate is flagged undervalued; meaningfully above it, overvalued. The estimate updates with each new financial analysis.

What is Intuitive Surgical, Inc.'s fair value estimate?

MoatScan AI derives Intuitive Surgical, Inc.'s (ISRG) fair value per share from a discounted cash flow (DCF) model built on the company's reported financials, analyst growth forecasts, and a discount rate reflecting its cost of capital. The Financial Analysis tab shows the estimate alongside every assumption behind it.

Back to Database

ISRG$378.81

Intuitive Surgical, Inc.

Last Updated

Aug 19, 20269 days ago

Moat & Trend

Management

AI Impact

Competitive Radar

Moat Score

65/100

Executive Summary

Intuitive Surgical’s moat is anchored by the da Vinci ecosystem: a massive installed base, surgeon training advantages, recurring instruments and service revenue, and a long record of regulatory clearances and clinical adoption. Those factors create meaningful lock-in for hospitals and strong preference among surgeons who have built their operating routines around the platform. The moat is not wide, however, because robotic surgery remains a contested market rather than a natural monopoly. Well-funded medtech rivals can still attack with alternative platforms, and hospitals can evaluate replacements over multi-year capital cycles. Intuitive’s edge is durable, but it is bounded by competition, pricing scrutiny, and the fact that customers can multi-home rather than being permanently captive.

Network Effects

Training Ecosystem Flywheel

Pillar Strength

4/10

Intuitive does not have a classic two-sided network in which each new customer dramatically increases value for every other customer, but it does benefit from a reinforcing ecosystem. The larger the da Vinci installed base, the more surgeons are trained on the platform, the more resident and fellowship programs teach it, and the more peers view it as the default robotic standard. That creates reference value and adoption momentum. Still, hospitals can compare multiple systems, surgeons can learn more than one platform, and clinical evidence is not exclusive. The reinforcement is meaningful, but it is one-sided and not fully self-propelling.

Switching Costs

Deep Workflow Lock-In

Pillar Strength

8/10

Switching costs are high because adoption of da Vinci is not just a purchase decision; it is a retraining and workflow decision. Hospitals commit capital for the system, then layer on maintenance contracts, disposable instruments, staff training, credentialing, operating-room redesign, and surgeon-specific case development. Once a team builds case volume and comfort on a platform, changing systems can interrupt throughput and raise clinical and reputational risk. The friction is not absolute, though. Large health systems can add competing robots over time, and a new capital cycle gives customers an opportunity to switch. Still, the operating disruption is substantial enough to deter churn.

Intangible Assets

Brand And Clearances

Pillar Strength

8/10

Intuitive has strong intangible assets in the form of brand, regulatory history, accumulated clinical evidence, and a large patent estate around robotic surgery workflows and instruments. The da Vinci name is synonymous with robotic-assisted surgery in many hospitals, and that recognition matters when clinicians and administrators evaluate risk. FDA approvals across multiple procedures also create a real credibility moat, since each new indication requires evidence, time, and investment. The limitation is that the underlying category is technologically replicable, and patents eventually age. Competitors can build robotic systems, but they cannot quickly replicate Intuitive’s brand trust, installed evidence base, and procedural familiarity.

Cost Advantages

Scale In Recurring Supply

Pillar Strength

5.5/10

Intuitive has some cost advantage from scale, especially in manufacturing, service infrastructure, and the recurring supply of instruments and accessories. A larger installed base lets the company spread support and R&D across more procedures, and the consumables model supports attractive economics. But this is not a decisive low-cost position. The systems themselves are expensive, service intensity is high, and hospitals still evaluate total procedure economics carefully. Rival manufacturers with enough capital can source components, automate assembly, and pursue similar recurring-revenue models. Intuitive’s scale helps, but the gap is better described as an operational edge than a structurally unassailable cost moat.

Efficient Scale

Few Serious Rivals

Pillar Strength

7/10

Robotic-assisted surgery is a market with high entry barriers and only a few serious contenders, which supports efficient scale. Building a credible platform requires large R&D budgets, clinical validation, regulatory clearance, service capability, and access to surgeon advocates. That makes it difficult for many small competitors to survive. Even so, the market is not a natural monopoly. Large medtech companies can and do invest, and some customers want alternatives for pricing or strategic reasons. Intuitive benefits from being the incumbent leader in a relatively concentrated field, but the field is concentrated because of execution barriers, not because only one provider can efficiently serve the entire market.

Moat Type & Trend

Why this company earns its moat rating, and where the moat is heading

Moat Type

Narrow Moat

Trend

Positive

Why This Rating

Intuitive Surgical has a durable advantage, but it is still concentrated in one platform and one surgical workflow rather than an economy-wide franchise. Hospitals value da Vinci’s installed base, surgeon familiarity, and broad clinical evidence, yet those assets do not make alternative robotic systems impossible to introduce or migrate to over time. In twenty years, the company should still be a leading robotic-surgery franchise, but the market will likely contain credible substitutes and competing ecosystems. That makes the protection real and durable, but not so dominant or self-reinforcing that it deserves a wide-moat label.

Why This Trend

The moat is strengthening because procedure volumes continue to expand across specialties and geographies, which deepens surgeon familiarity and spreads fixed training and service economics over a larger base. The installed base also keeps generating recurring instrument and service demand, reinforcing the ecosystem around da Vinci. To flip this to Stable, growth would need to normalize without meaningful share gains in new procedures; to turn Negative, rival systems would need to win primary placements at scale or compress Intuitive’s recurring revenue mix.

Management Quality Assessment

Evaluating leadership track record, capital allocation, and governance

Verdict

Strong

Intuitive’s management has been unusually consistent: Dave Rosa became CEO in July 2025 after nearly 30 years in operating roles at the company, following Gary Guthart’s 15-year CEO run that coincided with massive market-value creation. Capital allocation looks disciplined, with a five-year ROIC around 17% and recent ROIC near 20%, plus targeted acquisitions that expand distribution and informatics rather than empire-building. The business is not founder-led; it is run by long-tenured internal executives, which has supported continuity. Insider ownership appears meaningful but the direction is unclear; both Rosa and Guthart have sold shares. Rosa’s roughly $21 million pay is high, but mostly incentive-based and not obviously misaligned. No major governance red flags stand out.

Key Highlights

Dave Rosa is a 29-year Intuitive veteran who was promoted from president to CEO in July 2025, while predecessor Gary Guthart led the company for 15 years and remained in the chair role. That internal succession points to continuity rather than a disruptive leadership reset.
The company’s capital allocation record is strong: recent ROIC is about 20% and the five-year average is near 17%, indicating management has compounded value by reinvesting in high-return opportunities.
Intuitive has returned cash primarily through buybacks, completing roughly 29.4 million shares of repurchases for about $9.1 billion, while avoiding dividend commitments that could constrain reinvestment.
Recent M&A has been targeted and strategic, including direct distribution control in Southern Europe and the Orpheus Medical acquisition to deepen surgical video and data capabilities, rather than large, risky deals.
The board is almost entirely independent aside from the CEO and executive chair, which reduces governance risk; however, insider ownership trends are not clearly rising, and both Rosa and Guthart have been net sellers in recent filings.

AI Impact Assessment

Evaluating how AI strengthens or disrupts existing moat pillars

AI Opportunity

6/ 10

AI Threat

5/ 10

Net AI Impact

+1Neutral

Net Reinforcer. AI strengthens Intuitive Surgical’s moat where it already matters most: the proprietary procedure dataset, workflow integration, surgeon training ecosystem, and regulatory cadence. The company’s >20 million historical procedures and embedded analytics in da Vinci 5 and Case Insights give it a data advantage rivals cannot quickly replicate, and the FDA’s change-management pathway can turn iterative model updates into a deployment advantage. That said, AI is still primarily defensive here rather than a new profit pool. The main uncertainty is whether competitors can pair lower-cost robots with acceptable AI guidance fast enough to narrow Intuitive’s lead in selected specialties and pressure recurring instrument economics.

AI Opportunity Highlights

Intuitive’s >20 million historical procedures create a proprietary training set for surgical models that rivals with newer installed bases cannot match quickly.
da Vinci 5 and Case Insights embed AI into clinical workflow, giving Intuitive a way to deepen surgeon reliance rather than sell standalone software.
The company’s training, simulation, and analytics stack can improve surgeon onboarding and utilization, reinforcing adoption across high-volume soft-tissue specialties.
Using the FDA’s iterative update pathway can let Intuitive ship incremental AI improvements faster than rivals that face traditional re-clearance cycles.

AI Threat Highlights

Medtronic’s Hugo and other robotic platforms can use broadly available AI techniques to narrow the gap on guidance and analytics without Intuitive’s legacy cost structure.
Lower-cost competitors and Chinese manufacturers can increasingly replicate AI-enabled workflow features, making core robot functionality more price competitive.
AI does not protect the instrument consumables business if hospitals push harder on total cost of care and seek alternative or remanufactured accessories.
If AI reduces the learning-curve advantage of da Vinci, Intuitive’s surgeon-training moat could weaken in procedures where adoption was partly driven by ease of use.

Sign in to see the full analysis

The Strategic Factor Breakdown, Management Quality Assessment, and AI Impact Assessment are available to registered users — it's free.

Last Updated

Aug 9, 202619 days ago

Target Price

Analyst Consensus

FAIR VALUE

Financial Strength

Financial Score

85/100

Executive Summary

Intuitive Surgical’s defining strength is its exceptional financial resilience, anchored by a pristine balance sheet and highly profitable core operations. Revenue has compounded from $6.2 billion in FY2022 to $10.1 billion in FY2025, while gross margin has remained near 67% and operating margin has expanded to 29.3%, reflecting durable operating leverage and strong earnings quality. Cash generation is equally impressive, with operating cash flow and free cash flow both rising materially, although working capital—especially inventory—continues to absorb cash. Liquidity is outstanding, with current assets far exceeding current liabilities and minimal leverage, supporting substantial equity growth. The main tension is that top-line growth has recently moderated and asset turnover remains only moderate, even as expenses continue to rise. Overall, ISRG presents a high-quality, low-risk financial profile with strong profitability, liquidity, and growth momentum, consistent with its top-tier ratings across the analysis.

Income Statement

Revenue · Margins · Profitability

Section Score

8.5/10

Revenue has compounded strongly from 6.2bn in FY2022 to 10.1bn in FY2025, with growth accelerating through FY2024 before easing in TTM to 9.6% versus 20.5% in FY2025. Profitability is excellent: gross margin stayed near 67% and operating margin expanded from 25.3% to 29.3%, showing operating leverage even as SG&A and R&D rose steadily. Earnings quality looks strong and repeatable, with no obvious one-off distortions; pretax income and normalized net income track the underlying business well. Against typical medical device peers, these margins and growth rates are superior. Main flags are the recent growth deceleration and continued expense expansion, but overall the franchise remains highly durable and consistently profitable.

Financials are in millions USD unless otherwise specified

Metric	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Revenue	11,034.4	10,064.7	8,352.1	7,124.1	6,222.2
Revenue Growth	9.63%	20.51%	17.24%	14.49%	—
Net Income	3,138.8	—	—	—	—
Net Income Growth	—	—	—	—	—

Data as of Jun 30, 2026

Balance Sheet

Assets · Liabilities · Equity

Section Score

9.5/10

Intuitive Surgical’s balance sheet remains exceptionally strong. TTM current assets of $9.5B comfortably cover current liabilities of $1.9B, supported by $5.2B of cash and short-term investments and $7.6B of working capital. Total assets rose to $20.9B while total liabilities stayed modest at $2.6B, indicating very low leverage and a wide equity cushion. Shareholders’ equity increased steadily from $11.0B in FY2022 to $18.2B TTM, showing consistent internal capital generation. Inventory and receivables have grown, but not to a level that meaningfully weakens liquidity. Overall, the balance sheet shows excellent solvency, stable asset quality, and very limited structural risk.

Financials are in millions USD unless otherwise specified

Metric	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Current Assets	9,542.7	9,779.5	7,111	7,888	6,253	—
Total Assets	20,876.6	20,458.7	18,743.2	15,441.5	12,974	—
Total Current Liabilities	1,922.9	2,006.2	1,745.3	1,658.7	1,422.1	—
Total Liabilities	2,578.9	2,517	2,213.6	2,044.2	1,861.4	—

Data as of Jun 30, 2026

Cash Flow Statement

Operations · Investing · Financing

Section Score

8.5/10

Cash generation is strong and improving. Operating cash flow rose from $1.49B in FY2022 to $3.03B in FY2025, with TTM at $3.71B, which is higher than the latest full year and suggests continued momentum. Free cash flow is also healthy, increasing from $958M to $2.49B, and TTM FCF of $3.22B remains well supported after capital spending. Capex has been meaningful but manageable, indicating ongoing reinvestment rather than excess expansion. The main drag is working capital, especially inventory, which has been a persistent use of cash and widened to -$1.27B in FY2025. Capital returns are aggressive through buybacks, but the company still generates ample cash to fund them.

Financials are in millions USD unless otherwise specified

Metric	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Operating Cash Flow	3,706.4	3,030.5	2,415	1,813.8	1,490.8
Operating Cash Flow Growth	22.30%	25.49%	33.15%	21.67%	—
Free Cash Flow	3,222.6	2,490.7	1,303.8	749.6	958.4
Free Cash Flow Growth	29.39%	91.03%	73.93%	-21.79%	—

Data as of Jun 30, 2026

Key Ratios

Liquidity · Leverage · Efficiency · Returns

Section Score

8/10

Liquidity is exceptionally strong, with the current ratio, quick ratio, and cash ratio all far above normal levels across the period and still improving in TTM, indicating ample ability to cover short-term obligations. Leverage cannot be fully judged from the ratios provided because debt metrics are not included, but the balance-sheet liquidity profile suggests limited near-term stress. Efficiency is mixed: asset turnover is low but has improved to 0.53 in TTM, showing slightly better asset use. Profitability and returns are a clear strength, with operating margin, pre-tax margin, profit margin, ROE, and ROA all at healthy levels and trending higher overall, despite a modest gross margin decline. Overall, the profile is strong with only moderate efficiency concerns.

Ratios are dimensionless unless otherwise noted

Metric	Current	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	—	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Current Ratio	487.464	487.464	407.437	475.553	439.702
Quick Ratio	395.748	395.748	322.225	401.965	376.893
Profit Margin	28.38%	28.38%	27.81%	25.24%	21.25%
After Tax ROE	16.023	16.023	14.133	13.511	11.975
Return on Assets	15.04%	—	—	—	—
P/E Ratio	43.49	74.92	83.92	79.38	70.38
Forward P/E	31.38	58.82	67.57	52.63	48.31

Data as of Dec 31, 2025

Growth

Revenue · EPS · Valuation · Estimates

Section Score

8/10

ISRG shows a strong multi-year compounding pattern, with revenue rising from 6.22B USD to 10.06B USD and then continuing to 11.77B USD and 13.25B USD in the forward estimates. Growth accelerates through 2025, then moderates, suggesting a transition from rapid expansion to a still-healthy but more normalized pace. EPS has grown steadily from 3.65 to 7.87, and the forecast path to 10.79366 and 12.07083 indicates continued earnings expansion, with EPS growth generally outpacing revenue growth in the historical period, implying margin improvement. Analyst sentiment is constructive: a Buy consensus, a wide but positive target range, and 29 analysts provide solid coverage depth. The recommendation mix has been stable to slightly improving, with fewer bearish calls over recent months.

Analyst Price Targets

Low$324-14.47%

Median$483+27.50%

Average$477.25+25.99%

High$685+80.83%

BuyConsensus rating based on analyst coverage

29 analysts

Recommendation Trends

Rating	Aug '26	Jul '26	Jun '26	May '26
Strong Buy	7	7	6	6
Buy	16	16	16	16
Hold	9	9	9	9
Sell	1	1	1	1
Strong Sell	0	0	1	1
Total	33	33	33	33

Forecast · Analyst Estimates

Revenue This Year11.77B

+16.97%from 10.06B

FY 2026

Revenue Next Year13.25B

+12.54%from 11.77B

FY 2027

EPS This Year· non-GAAP adj.10.79

+20.87%

FY 2026

EPS Next Year· non-GAAP adj.12.07

+11.83%

FY 2027

Historical · Reported Actuals

Metric	FY 2025	FY 2024	FY 2023	FY 2022
Revenue	10.06B	8.35B	7.12B	6.22B
Revenue Growth	+20.51%	+17.24%	+14.49%	—
EPS (GAAP diluted)	7.87	6.42	5.03	3.65
EPS Growth	+22.59%	+27.63%	+37.81%	—

Revenue in USD · EPS per share · Price targets in USD

Data as of Dec 31, 2025 · Forecast EPS is analyst non-GAAP adjusted; historical EPS is GAAP diluted — not directly comparable.

Fair Value Estimation

DCF · -10.5% Margin of Safety · Fairly Valued

AI Fair Value Estimate (DCF)

$339.12vs$378.81

Margin of Safety-10.5%

Fairly Valued — Trading near intrinsic value

A discounted cash flow framework fits Intuitive Surgical because the business is highly cash-generative, with a long runway of predictable procedure-driven growth and recurring economics that can be translated into a multi-year operating ramp. The projected cash-flow path points to expanding scale, durable margin strength, and disciplined capital intensity, while the slower rise in free cash flow versus revenue suggests growth moderates over time as the business matures and capex stays contained.

AI Valuation Verdict

A 7-year DCF is appropriate for Intuitive Surgical because its operating model combines strong cash generation with a relatively visible growth trajectory and recurring demand dynamics. The valuation is most sensitive to the 7.7% discount rate, the 4% terminal growth assumption, and whether EBITDA margins remain near the mid-40% range as the company scales. On this basis, fair value is $339.12 per share versus a current price of $378.81, implying a -10.48% margin of safety and a Fairly Valued verdict. A stronger case would require more durable margin expansion or faster cash conversion; the bear case rests on margin compression, slower growth fade, or a higher cost of capital.

DCF Assumptions

WACC

7.7%

Weighted avg cost of capital

Revenue Growth (7Y)

9.2%

CAGR assumption

EBITDA Margin

42.9%

Steady-state projection

CapEx / Revenue

9.7%

Capital investment

Terminal Growth

4.0%

Long-run growth rate

Projection Period

7 yrs

Explicit forecast horizon

Projected Cash Flows

Values in millions USD

Year	Revenue	EBITDA	FCF	Discounted FCF
Yr 1	11,535	4,444	2,478	2,301
Yr 2	12,625	5,124	3,087	2,661
Yr 3	14,149	5,898	3,510	2,810
Yr 4	15,534	6,675	4,119	3,061
Yr 5	16,897	7,613	4,843	3,342
Yr 6	18,577	8,419	5,232	3,353
Yr 7	19,531	8,959	5,825	3,466
Terminal Value (PV)				97,413

Sign in to see the full analysis

The Income Statement, Balance Sheet, Cash Flow, Key Ratios, Forecast, and Fair Value analysis are available to registered users — it's free.

Last Updated

Aug 9, 2026

Short Term

Medium Term

Long Term

Price Outlook

$378.81Price at Analysis

The path of least resistance in the near term is modestly higher toward $379.89 and potentially $388.45 if buyers can hold the $374.34 to $370.89 support band. The key downside risk is a failure back below $374.34, which would likely shift attention toward $367.06 and then the weekly pivot at $357.14.

Technical Overview

ISRG’s technical profile is mixed at the tactical level but still decisively impaired on the broader trend. Short-term momentum has improved enough to keep the stock above its 20-day average, with bullish MACD and a constructive RSI reading, yet that strength is fragile given contracting volume and the sharp daily selloff. Medium- and long-term signals remain aligned to the downside: price is below the 50-day and 200-day moving averages, the stock is in Death Cross territory, and it sits in the lower third of its 52-week range. The most relevant levels to monitor are $379.89 and $384.38 on the upside, versus $374.34 and $370.89 on the downside, with the monthly $331.21 support zone defining the broader structural floor.

Short Term

1 to 4 weeks

Bullish

ISRG’s short-term setup remains constructive because price is still above the 20-day moving average, RSI sits in a bullish zone at 62.5, and MACD is positive versus its signal line. That said, the 15.68% one-day decline and contracting relative volume temper conviction, suggesting upside may be more tactical than impulsive.

Key Indicators

Price vs 20-day MA+3.98% above

Price vs 50-day MA-3.65% below

RSI (14-day)62.5

RSI InterpretationApproaching overbought

MACD TrendBullish (above signal)

Bollinger PositionUpper half

Volume TrendContracting

Support

$374.34$369.84$367.06

Resistance

$379.89$384.38$388.87

The closest short-term level is resistance at $379.89, just above the current price, with support at $374.34 immediately below. In the 1–4 week window, a test of $379.89 is likely, while a break back under $374.34 would expose $369.84 and $367.06.

Medium Term

1 to 6 months

Bearish

The medium-term picture is negative: price remains below both the 50-day and 200-day moving averages and the stock is still in Death Cross territory. With the broader trend direction pointing lower and the shares positioned in the lower third of the 52-week range, rallies are likely to face overhead supply.

Key Indicators

Price vs 50-day MA-3.65% below

Price vs 200-day MA-21.11% below

52-Week Range PositionLower third (18%)

Trend DirectionDowntrend

MA Cross SignalDeath Cross territory

Relative Volume0.56x avg

Support

$376.49$370.89$345.18

Resistance

$388.45$402.20

Weekly pivots show nearby support at $376.49 and $370.89, with resistance at $388.45 and then $402.2. The 50-day moving average sits above this zone, creating a meaningful confluence ceiling near the upper-$380s to low-$390s that is likely to be tested only if momentum improves.

Long Term

6 months and beyond

Very Bearish

Long-term structure is still weak, as ISRG trades more than 21% below the 200-day moving average and remains in a persistent downtrend. The stock is also deep in the lower third of its 52-week range, and the recent Death Cross reinforces a durable bearish regime despite a not-yet-oversold RSI.

Key Indicators

Price vs 200-day MA-21.11% below

52-Week High$603.88

52-Week Low$328.57

Distance from 52w High-37.3%

BB Bandwidth22.1%

MA CrossoverRecent Death Cross (97 days ago)

Support

$331.21$306.65$304.01

Resistance

$419.28$421.92$446.48

Monthly structure defines broader boundaries around support at $331.21 and $306.65, while resistance remains layered at $419.28 and $421.92 before $446.48. Over 6+ months, the key question is whether price can stabilize above the mid-$300s or continue to probe the lower monthly support band rather than reclaim the 52-week high area.

Sign in to see the full analysis

See the full short, medium & long-term indicator breakdowns and support/resistance levels — free for registered users.

Frequently asked questions about Intuitive Surgical, Inc.

Does Intuitive Surgical, Inc. (ISRG) have an economic moat?: MoatScan AI rates Intuitive Surgical, Inc. (ISRG) 65/100 for moat strength, assessed across five sources of competitive advantage: network effects, switching costs, intangible assets, cost advantages and efficient scale. Intuitive Surgical’s moat is anchored by the da Vinci ecosystem: a massive installed base, surgeon training advantages, recurring instruments and service revenue, and a long record of regulatory clearances and clinical…Sign in free to see the Moat Type verdict and the pillar-by-pillar reasoning.
What is Intuitive Surgical, Inc.'s moat score?: Intuitive Surgical, Inc. (ISRG) has a moat score of 65/100. The score is a weighted average of five pillar ratings: network effects, switching costs, intangible assets, cost advantages, and efficient scale. A higher score means the competitive advantages MoatScan AI identifies are wider and more durable.Sign in free to see each pillar rating, the Moat Type verdict and the moat trend.
Is ISRG stock overvalued or undervalued?: MoatScan AI answers this by estimating ISRG's intrinsic value with a discounted cash flow (DCF) model, then comparing that estimate to the current market price. A share price meaningfully below the estimate is flagged undervalued; meaningfully above it, overvalued. The estimate updates with each new financial analysis.Sign in free to see the fair value estimate, the implied upside or downside, and the verdict.
What is Intuitive Surgical, Inc.'s fair value estimate?: MoatScan AI derives Intuitive Surgical, Inc.'s (ISRG) fair value per share from a discounted cash flow (DCF) model built on the company's reported financials, analyst growth forecasts, and a discount rate reflecting its cost of capital. The Financial Analysis tab shows the estimate alongside every assumption behind it.Sign in free to see the estimate and the full assumptions behind it.

Disclaimer: The analysis on this page is generated by AI and is provided for informational purposes only. It does not constitute financial advice, investment recommendations, or an offer to buy or sell any security. Always conduct your own due diligence and consult a qualified financial adviser before making any investment decisions.

ISRG$378.81

Sign in to see the full analysis

Sign in to see the full analysis

Sign in to see the full analysis

Frequently asked questions about Intuitive Surgical, Inc.

Other Narrow Moat companies